CDX-585 for Cancer

Recruiting in Palo Alto (17 mi)

+3 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Celldex Therapeutics

No Placebo Group

Trial Summary

What is the purpose of this trial?This is an open-label, non-randomized, multicenter, dose-escalation and expansion study in patients with selected solid tumors.

Eligibility Criteria

This trial is for adults with various advanced cancers who've had standard treatment. They must be willing to use birth control and undergo biopsies. It's not for those with brain tumors, recent thrombosis, active pneumonitis, untreated brain metastases, autoimmune diseases, or a history of severe reactions to monoclonal antibodies.

Inclusion Criteria

If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment

I have received standard treatment for my cancer in its advanced stages.

I am willing to have biopsies before and during treatment if needed.

+2 more

Exclusion Criteria

I haven't had anti-PD-L1 therapy in the last 12 weeks or anti-PD-1 therapy in the last 4 weeks.

I've been cancer-free for a year, except for minor skin cancers or in situ cancers.

History of severe hypersensitivity reactions to other monoclonal antibodies

+6 more

Participant Groups

CDX-585 is being tested in this study where all participants receive the drug openly without randomization. The trial aims to find the right dose and see how well it works across different types of advanced solid tumors.

1Treatment groups

Experimental Treatment

Group I: CDX-585Experimental Treatment1 Intervention

Dose-escalation phase: Eligible patients will receive treatment, based on cohort assigned, in 2-week cycles until progression or intolerance. Expansion phase: Patients enrolled in the expansion phase of the study will receive CDX-585 at the dose level chosen during the escalation phase.